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2007-2008 Influenza Season 
Week 14, ending April 5, 2008 
 (All data are preliminary and may change as more reports are received.) 
Synopsis:  During week 14 (March 30 – April 5, 2008), influenza activity continued to decrease in 
the United States.   
o Three hundred seventy-six (13.2%) specimens tested by U.S. World Health Organization 
(WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) 
collaborating laboratories were positive for influenza. 
o The proportion of deaths attributed to pneumonia and influenza has been above the 
epidemic threshold for 13 consecutive weeks. 
o The proportion of outpatient visits for influenza-like illness (ILI) and the proportion of 
outpatient visits for acute respiratory illness (ARI) were below national baseline levels. ILI 
decreased in all nine regions compared to week 13, but remained above the region-specific 
baselines in the East North Central and West North Central regions.  The proportion of 
outpatient visits reported for ARI was below all region and age-specific baselines.   
o Six states reported widespread influenza activity; 11 states reported regional influenza 
activity; 23 states reported local influenza activity; and 10 states and the District of Columbia 
reported sporadic influenza activity.  
 
National and Regional Summary of Select Surveillance Components 
  Data for current week Data cumulative for the season 
  
Sentinel 
Provider 
ILI* 
DoD and 
VA ARI* 
% pos. 
for flu†
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity‡  
A 
(H1) 
A 
(H3) 
A 
Unsub-
typed 
B Pediatric Deaths 
Nation Normal Normal 13.2% 17 of 51  2110 5605 17741 8924 65 
New 
England Normal Normal 17.3% 4 of 6 94 183 928 932 7 
Mid-
Atlantic Normal Normal 21.3% 3 of 3 209 316 1155 1262 12 
East North 
Central Elevated Normal 24.0% 1 of 5 178 1297 441 489 8 
West 
North 
Central Elevated Normal 21.7% 2 of 7 104 190 2679 1307 6 
South 
Atlantic Normal Normal 18.2% 1 of 9 343 1746 4612 1483 6 
East 
South 
Central Normal Normal 21.0% 0 of 4 37 751 100 94 6 
West South 
Central Normal Normal 12.1% 0 of 4 109 484 5943 1604 8 
Mountain Normal Normal 12.5% 1 of 8 526 442 969 1029 5 
Pacific Normal Normal 12.6% 5 of 5 510 196 914 724 7 
* Elevated means the % of visits for ILI or ARI is at or above the national or region-specific baseline 
† National data are for current week; regional data are for the most recent three weeks 
‡ Includes all 50 states and the District of Columbia 
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Laboratory Surveillance:  During week 14, WHO and NREVSS laboratories reported 2,839 
specimens tested for influenza viruses, 376 (13.2%) of which were positive, including 13 influenza A 
(H3) viruses, 166 influenza A viruses that were not subtyped, and 197 influenza B viruses.   
 
Since September 30, 2007, WHO and NREVSS laboratories have tested a total of 185,938 
specimens for influenza viruses and 34,380 (18.5%) were positive. Among the 34,380 influenza 
viruses, 25,456 (74.0%) were influenza A viruses and 8,924 (26.0%) were influenza B viruses.  
Seven thousand seven hundred fifteen (30.3%) of the 25,456 influenza A viruses have been 
subtyped: 2,110 (27.3%) were influenza A (H1) viruses and 5,605 (72.7%) were influenza A (H3) 
viruses. 
 
During the 2007-08 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United 
States.  Influenza A (H3) viruses have predominated during the season overall, however, the most 
commonly reported influenza virus has varied by week.  From week 40 through week 3 (September 
30, 2007 – January 19, 2008) influenza A (H1) viruses were more frequently reported; from week 4 
through week 12 (January 20 – March 22, 2008), influenza A (H3) viruses were more commonly 
reported; and for weeks 13 through 14 (March 23 – April 5, 2008), more influenza B than influenza 
A viruses were reported.  The predominant virus has also varied by region.  Influenza A (H3) 
viruses have been reported more frequently than A (H1) viruses in seven of the nine surveillance 
regions (East North Central, East South Central, Mid-Atlantic, New England, South Atlantic, West 
North Central, and West South Central) while influenza A (H1) viruses have predominated 
circulation this season in two regions (Mountain and Pacific). 
U.S. WHO/NREVSS Collaborating Laboratories
National Summary, 2007-08
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Composition of the 2008-09 Influenza Vaccine:  WHO and FDA have recommended that the 
2008-09 trivalent influenza vaccine for the Northern Hemisphere contain A/Brisbane/59/2007-like 
(H1N1), A/Brisbane/10/2007-like (H3N2), and B/Florida/4/2006-like viruses.  All three components 
have been changed from the 2007-08 Northern Hemisphere vaccine formulation.  
A/Brisbane/10/2007-like (H3N2) and B/Florida/4/2006-like viruses are currently included in the 2008 
Southern Hemisphere vaccines.  This recommendation was based on surveillance data related to 
epidemiology and antigenic characteristics, serological responses to 2007-08 vaccines, and the 
availability of candidate strains and reagents. 
2007-2008 Influenza Season – Week 14, ending April 5, 2008           
 
3
 
Antigenic Characterization:  CDC has antigenically characterized 608 influenza viruses [290 
influenza A (H1N1), 161 influenza A (H3N2), and 157 influenza B viruses] collected by U.S. 
laboratories since September 30, 2007. 
 
Influenza A (H1N1) [290] 
• Two hundred (69%) of the 290 viruses were characterized as A/Solomon 
Islands/3/2006-like, the influenza A (H1N1) component of the 2007-08 influenza 
vaccine for the Northern Hemisphere and the 2008 influenza A (H1N1) component 
for the Southern Hemisphere. 
• Twenty (7%) of the 290 viruses showed somewhat reduced titers with antisera 
produced against A/Solomon Islands/3/2006. 
• Seventy (24%) of the 290 viruses were characterized as A/Brisbane/59/2007-like. 
A/Brisbane/59/2007 is a recent genetic/antigenic variant which evolved from 
A/Solomon Islands/03/2006. An A/Brisbane/59/2007-like virus is the WHO 
recommended strain for the 2008-09 Northern Hemisphere vaccine formulation. 
Influenza A (H3N2) [161] 
• Thirty-five (22%) of the 161 viruses were characterized as A/Wisconsin/67/2005-like, 
the influenza A (H3N2) component of the 2007-08 influenza vaccine for the Northern 
Hemisphere. 
• One hundred fifteen (71%) of the 161 viruses were characterized as 
A/Brisbane/10/2007-like.  A/Brisbane/10/2007-like viruses are a recent antigenic 
variant which evolved from, but are antigenically distinct from, A/Wisconsin/67/2005-
like viruses.  A/Brisbane/10/2007-like virus is the recommended influenza A (H3N2) 
component for the 2008 Southern Hemisphere and 2008-09 Northern Hemisphere 
vaccines. 
• Eleven (7%) of the 161 viruses showed somewhat reduced titers with antisera 
produced against A/Wisconsin/67/2005 and A/Brisbane/10/2007. 
 
Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [157] 
Victoria lineage [8] 
• Eight (5%) of the 157 influenza B viruses characterized belong to the B/Victoria 
lineage of viruses. 
o Six (75%) of these 8 viruses were characterized as B/Ohio/01/2005-like. The 
recommended influenza B component for the 2007-08 influenza vaccine is a 
B/Malaysia/2506/2004-like virus, belonging to the B/Victoria lineage.  
B/Ohio/01/2005 is a recent B/Malaysia/2506/2004-like reference strain. 
o Two (25%) of these 8 viruses showed somewhat reduced titers with antisera 
produced against B/Ohio/01/2005 and B/Malaysia/2506/2004.  
Yamagata lineage [149] 
• One hundred forty-nine (95%) of the 157 influenza B viruses characterized belong to 
the B/Yamagata lineage of viruses.   
o One hundred forty-eight (99%) of these 149 viruses were identified as 
B/Florida/04/2006-like, the recommended influenza B component for the 
2008-09 Northern Hemisphere vaccine formulation. 
o One (1%) of these 149 viruses showed a somewhat reduced titer with 
antiserum produced against B/Florida/04/2006.  
 
These data indicate similarities and differences between a sample of circulating strains and this 
year's vaccine strains as determined by laboratory studies. Clinical vaccine effectiveness cannot be 
accurately predicted using these data, and in previous years, influenza vaccination has been shown 
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to provide measurable protection against influenza illness and influenza-related complications, even 
when vaccine strains are antigenically distinct from circulating strains. 
 
Antiviral Resistance: In the United States, two groups of antiviral drugs have been approved by 
FDA for use in treating or preventing influenza virus infections.  These two groups of antiviral drugs 
are: neuraminidase inhibitors (oseltamivir and zanamivir) and adamantanes (amantadine and 
rimantadine). A description of these drugs can be found at: 
http://www.cdc.gov/flu/protect/antiviral/index.htm.  
 
Neuraminidase Inhibitor Antiviral Drugs:  So far this season, 1,153 influenza A and B 
viruses from the United States have been tested for antiviral resistance.  Eighty-four (8.3%) 
of 1,018 influenza A viruses tested, and 0 (0.0%) of 135 influenza B viruses tested have 
been found to be resistant to oseltamivir.  Currently all of the resistant viruses are influenza 
A (H1N1) viruses, with 84 (10.2%) of 824 influenza A (H1N1) viruses tested exhibiting a 
genetic mutation that confers oseltamivir resistance.  All tested viruses retain their sensitivity 
to zanamivir.  Additional information on antiviral resistance can be found at: 
http://www.cdc.gov/flu/about/qa/antiviralresistance.htm 
 
Adamantane Antiviral Drugs: Resistance to the adamantanes continues to be high among 
influenza A (H3N2) viruses with 260 (99.6%) of 261 influenza A (H3N2) viruses tested 
resistant to the adamantanes.  Adamantane resistance among influenza A (H1N1) viruses 
has also been detected but at a lower level. Of 729 influenza A (H1N1) viruses tested, 81 
(11.1%) were resistant to the adamantanes.  The adamantanes are not effective against 
influenza B viruses.  Since late January, influenza A (H3N2) viruses have predominated in 
the United States, and during week 14, 100% of influenza A viruses subtyped were A 
(H3N2).  
 
Based on the level of oseltamivir resistance observed in only one influenza subtype, H1N1, 
persisting high levels of resistance to the adamantanes in H3N2 viruses, and the 
predominance of H3N2 viruses circulating in the United States during the 2007-08 season 
with co-circulation of influenza B viruses, CDC continues to recommend the use of 
oseltamivir and zanamivir for the treatment or prevention of influenza.  Use of amantadine or 
rimantadine is not recommended.  Guidance on influenza antiviral use can be found at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5606a1.htm 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 14, 8.9% of all deaths 
reported through the 122 Cities Mortality Reporting System were reported as due to P&I. This 
percentage is above the epidemic threshold of 6.9% for week 14.  Including week 14, P&I mortality 
has been above epidemic threshold for 13 consecutive weeks. 
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Influenza-Associated Pediatric Mortality: Six influenza-associated pediatric deaths were reported 
to CDC during week 14 (CT, IL, NY, TN, TX, and VA).  These deaths occurred between February 5 
and March 30, 2008. Since September 30, 2007, CDC has received a total of 65 reports of 
influenza-associated pediatric deaths that occurred during the current season.   
Number of Influenza-Associated Pediatric Deaths
by Week of Death:
2005-06 season to present
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Influenza-Associated Pediatric Hospitalizations:  Laboratory-confirmed influenza-associated 
pediatric hospitalizations are monitored in two population-based surveillance networks: the New 
Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP).  These two 
systems provide updates of surveillance data every two weeks.  As a result of differing dates for 
initiating surveillance in the 2007-08 season, these updates occur on alternating weeks.  
During November 4, 2007-March 22, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate reported by the NVSN for children 0-4 years old was 5.61 per 
10,000. 
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During September 30 – March 29, 2008, the preliminary laboratory-confirmed influenza-associated 
hospitalization rate reported by the EIP for children 0–17 years old was 1.32 per 10,000.  For 
children aged 0-4 years and 5-17 years, the rate was 3.47 per 10,000 and 0.45 per 10,000, 
respectively.  
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children Aged 0-4 and 5-17 yrs, 2007-2008 and 
Previous 2 Seasons
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Outpatient Illness Surveillance:  Nationwide during week 14, 1.7% of outpatient visits reported 
through the U.S. Influenza Sentinel Provider Surveillance Network were due to influenza-like illness 
(ILI), which was below the national baseline of 2.2%.  On a regional level, the percentage of 
outpatient visits for ILI decreased in all nine regions compared to week 13 and ranged from 1.0% to 
3.0%.  Two of the nine regions reported ILI above their region-specific baselines (East North 
Central and West North Central), while the remaining seven regions (East South Central, Mid-
Atlantic, Mountain, New England, Pacific, South Atlantic, and West South Central) reported ILI 
below their region-specific baselines. 
During week 14, 2.2% of patient visits to Department of Veteran’s Affairs (VA) and Department of 
Defense (DoD) outpatient treatment facilities were for acute respiratory illness (ARI), which was 
below the national baseline of 3.2%.  On a regional level, the percentage of visits for ARI ranged 
from 1.3% to 2.5%, and was below region-specific baselines in all nine regions.  All five age groups 
reported ARI below their age-specific baselines.   
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Percentage of Visits for ILI & ARI Reported
by Sentinel Providers and BioSense Outpatient Facilities,
National Summary
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Percentage of Visits for ARI by Age Group Reported by 
DoD/VA Outpatient Clinics - National Summary
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: During 
week 14 the following influenza activity was reported: 
• Widespread activity was reported by six states (Connecticut, Maine, Maryland, New York, 
Pennsylvania, and Vermont). 
• Regional activity was reported by 11 states (Alaska, California, Colorado, Hawaii, Illinois, 
Iowa, Massachusetts, New Jersey, North Dakota, Oregon, and Washington). 
• Local influenza activity was reported by 23 states (Alabama, Arizona, Georgia, Idaho, 
Indiana, Kentucky, Louisiana, Michigan, Minnesota, Montana, Nebraska, Nevada, New 
Hampshire, New Mexico, North Carolina, Ohio, Rhode Island, South Carolina, South 
Dakota, Texas, Utah, Virginia, and Wyoming). 
• Sporadic influenza activity was reported by the District of Columbia and 10 states (Arkansas, 
Delaware, Florida, Kansas, Mississippi, Missouri, Oklahoma, Tennessee, West Virginia, and 
Wisconsin). 
 
 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: April 11, 2008.
  
  
